canada clinical guidance

Benign paroxysmal positional vertigo (BPPV)

A Canadian clinical summary of benign paroxysmal positional vertigo (bppv), with source-attributed priorities and explicit jurisdiction boundaries.

JurisdictionCanada
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceHealthcare professionals practising in Canada
This is an iatroX educational summary of named Canada sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.

Source and scope

This summary is bounded to the recommendations, population and decisions covered by Clinical diagnosis of benign paroxysmal positional vertigo and vestibular neuritis. Apply it with the current provincial or territorial pathway where implementation differs.
sources for this section:CMAJ BPPV

Source-attributed clinical priorities

  • Use timing, triggers and targeted eye and neurologic examination to distinguish positional vertigo from a central syndrome.
  • Confirm posterior-canal BPPV with positional testing when safe and treat with an appropriate canalith-repositioning manoeuvre.
  • Escalate new focal deficits, inability to walk, severe headache, central nystagmus or an atypical course.
  • The characteristic positional nystagmus pattern identifies the affected canal and the appropriate manoeuvre.
sources for this section:CMAJ BPPV

Practical assessment and management workflow

1
Clarify brief triggered episodes versus continuous vertigo and ask about hearing, headache, gait and neurologic symptoms.
2
Perform eye movements, gait and focused neurologic examination before positional testing.
3
Use the Dix-Hallpike or roll test when cervical and vascular safety permit.
4
Repeat the matched repositioning manoeuvre and reassess residual dizziness or an atypical response.
sources for this section:CMAJ BPPV

Safety, red flags and urgent escalation

  • Continuous vertigo with severe gait inability, focal findings or new headache requires central-cause assessment.
  • Do not rely on symptom description alone when stroke risk or abnormal examination is present.
  • Avoid prolonged vestibular suppressants because they do not correct canalith disease and can increase falls.
sources for this section:CMAJ BPPV

Confirm the local pathway before acting

The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.
sources for this section:CMAJ BPPV

Source and implementation boundary

Read this educational summary with the linked source, current Canadian product information where medicines are involved, and the applicable provincial or territorial pathway. Local formularies, reporting duties, referral routes and service availability can differ.
sources for this section:CMAJ BPPV

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. Canadian Medical Association JournalClinical diagnosis of benign paroxysmal positional vertigo and vestibular neuritis2020;192:E182-E186 路 accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Found a source update or regional discrepancy? Tell the iatroX editorial team.